Eli Lilly will acquire Morphic Holding for $3.2 billion, and the deal brings a phase 2b asset MORF-057 for the treatment of inflammatory bowel disease, and a preclinical pipeline. Eli Lilly to acquire ...
A biotech firm founded by Harvard Medical School chemist and molecular biologist Timothy Springer will become part of Eli Lilly and Company’s R&D pipeline following a $3.2 billion acquisition. Lilly ...
Positive Phase 2a data: MORF-057 demonstrated a statistically significant reduction in RHI score and a clinical remission rate of 25.7% (mMCS), supporting our bullish thesis on Morphic Therapeutic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results